EGFR<sup>T790M/L858R</sup>

By Targets:	5 alpha Reductase (1) 5-HT Receptor (5) Acetolactate Synthase (ALS) (1) Ack1 (1) ADC Cytotoxin (1) ADC Linker (1) Adenosine Receptor (1) Adrenergic Receptor (5) Akt (11) AMPK (1) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (9) Androgen Receptor (2) Angiotensin Receptor (1) Antibiotic (28) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (151) Aurora Kinase (2) Autophagy (92) Bacterial (44) Bcl-2 Family (3) Bcr-Abl (2) BCRP (1) BMX Kinase (2) Btk (14) c-Fms (1) c-Kit (3) c-Met/HGFR (12) Calcineurin (1) Calcium Channel (17) CaMK (2) Cannabinoid Receptor (2) Casein Kinase (3) Caspase (3) CDK (14) Checkpoint Kinase (Chk) (1) Cholecystokinin Receptor (2) COX (13) CRISPR/Cas9 (1) Cytochrome P450 (1) Dihydrofolate reductase (DHFR) (3) Dipeptidyl Peptidase (3) Discoidin Domain Receptor (1) DNA-PK (1) DNA/RNA Synthesis (51) Dopamine Receptor (1) Drug Metabolite (12) Drug-Linker Conjugates for ADC (3) Dynamin (1) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (1) EAAT (1) EGFR (471) Endogenous Metabolite (412) Enterovirus (1) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (7) Estrogen Receptor/ERR (7) Factor Xa (1) FAK (1) Ferroptosis (26) FGFR (7) FKBP (1) Flavivirus (1) FLT3 (1) Fluorescent Dye (6) Fungal (3) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (4) Gap Junction Protein (1) Glucocorticoid Receptor (1) Glutathione Reductase (1) Glutathione S-transferase (1) GlyT (1) GnRH Receptor (1) GPR35 (1) HBV (2) HCV (6) HCV Protease (1) HDAC (3) Hexokinase (2) HIF/HIF Prolyl-Hydroxylase (6) Histamine Receptor (1) Histone Acetyltransferase (2) Histone Demethylase (1) Histone Methyltransferase (2) HIV (13) HIV Protease (1) HMG-CoA Reductase (HMGCR) (2) HPV (1) HSP (3) HSV (7) IGF-1R (1) iGluR (8) IKK (3) Imidazoline Receptor (1) Influenza Virus (14) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (475) Itk (3) JAK (9) JNK (3) Keap1-Nrf2 (2) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) MEK (2) mGluR (13) Microtubule/Tubulin (5) Mitochondrial Metabolism (2) Mitophagy (6) Molecular Glues (1) Monoamine Oxidase (2) mTOR (4) Na+/K+ ATPase (3) Necroptosis (1) Neprilysin (2) NF-κB (7) NO Synthase (12) Nucleoside Antimetabolite/Analog (46) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) Orthopoxvirus (9) Oxidative Phosphorylation (1) P-glycoprotein (1) P2Y Receptor (2) p38 MAPK (5) PAK (3) Parasite (15) PARP (6) PD-1/PD-L1 (1) PDGFR (9) Phosphatase (6) Phosphodiesterase (PDE) (3) Phospholipase (1) PI3K (4) PI4K (1) Pim (1) PKA (2) PKC (2) Polo-like Kinase (PLK) (1) Potassium Channel (8) PPAR (2) Progesterone Receptor (4) Prostaglandin Receptor (1) PROTAC Linkers (4) PROTACs (19) Proton Pump (1) Raf (9) RAR/RXR (1) Ras (2) Reactive Oxygen Species (29) RET (4) Reverse Transcriptase (4) ROR (1) RSV (2) SARS-CoV (8) Serotonin Transporter (1) Sirtuin (3) Small Interfering RNA (siRNA) (3) Sodium Channel (8) SphK (2) Src (9) STAT (8) Survivin (1) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (1) TGF-beta/Smad (3) Thrombin (2) Thrombopoietin Receptor (1) Thymidylate Synthase (3) Thyroid Hormone Receptor (3) Topoisomerase (6) Trk Receptor (4) TRP Channel (3) Tyrosinase (2) VD/VDR (3) VEGFR (30) Wnt (1)
By Research Areas:	Cancer (700) Cardiovascular Disease (38) Endocrinology (21) Infection (90) Inflammation/Immunology (73) Metabolic Disease (186) Neurological Disease (86)
Click Chemistry:	Labeling and Fluorescence Imaging (2) Azide (3) Tetrazine (1) Alkynes (24)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149824

EGFR T790M/L858R-IN-2	EGFR Apoptosis	Cancer
EGFR T790M/L858R-IN-2 is a potent and selective *EGFRT790M/L858R* inhibitor with IC₅₀ values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFR T790M/L858R-IN-2 decreases the expression of p-EGFR, P-AKT, P-ERK1/2. EGFR T790M/L858R-IN-2 induces Apoptosis and cell cycle arrest in the G1 phase. EGFR T790M/L858R-IN-2 shows anti-cancer activity .

HY-157398

EGFR T790M/L858R-IN-3	EGFR	Cancer
EGFR T790M/L858R-IN-3 (compound B1) is a EGFR ^L858R/T790M inhibitor with IC₅₀ value of 13?nM. EGFR T790M/L858R-IN-3 shows anti-tumour activity in H1975 cells with an IC₅₀ value of 0.087 μΜ. EGFR T790M/L858R-IN-3 inhibits cell migration in A549 cells and induces apoptosis in H1975 cells .

HY-162062

EGFR WT/T790M/L858R-IN-1	EGFR	Cancer
EGFR WT/T790M/L858R-IN-1 (compound 10d) is a potent *EGFR* inhibitor, with IC₅₀s of 0.097, 0.280, and 0.051?μM for EGFR ^WT, EGFR ^T790M, and EGFR ^L858R, respectively. EGFR WT/T790M/L858R-IN-1 can be used for the research of cancer .

HY-142519

EGFR-IN-27	EGFR	Cancer
EGFR-IN-27 is a potent EGFR inhibitor with IC₅₀s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511) .

HY-142512

EGFR-IN-24

EGFR Cancer

EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively .

EGFR-IN-24	EGFR	Cancer
EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively .

HY-162299

EGFR kinase inhibitor 3	EGFR	Cancer
EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric *EGFR* kinase inhibitor with IC₅₀s of <10 nM, 1.5 nM, 0.059 nM, 0.064 nM for WT EGFR, EGFR-activating mutations L858R, L858R/T790M and L858R/T790M/C797S, respectively. EGFR kinase inhibitor 3 is a C-linked inhibitor .

HY-157994

EGFR WT/T790M-IN-2	EGFR Apoptosis	Cancer
EGFR WT/T790M-IN-2 (Compound 7c) is a **EGFR T790M/WT inhibitor with IC₅₀** values of 0.08 and 0.13 μM, respectively. EGFR WT/T790M-IN-2 induces apoptosis by blocking the G0-G1 phase (apoptosis). EGFR WT/T790M-IN-2 has antitumor activity .

HY-163371

EGFR WT/T790M-IN-1	EGFR Apoptosis	Cancer
EGFR WT/T790M-IN-1 (Compound 16h) is a dual EGFR WT and **EGFR T790** inhibitor. EGFR WT/T790M-IN-1 can arrest the cell cycle in G2/M phase and induce apoptosis. EGFR WT/T790M-IN-1 has anti-cancer activity .

HY-162254

EGFR/ACK1-IN-1	EGFR Ack1	Cancer
EGFR T790M/L858R/ACK1-IN-1 is a dual inhibitor of **EGFR T790M/L858R and ACK1. IC₅₀** values are 23 and 263 nM, respectively. EGFR T790M/L858R/ACK1-IN-1 can inhibit cell proliferation and has antitumor activity .

HY-111415

EGFR-IN-5

EGFR Cancer

EGFR-IN-5 is a EGFR inhibitor with IC₅₀s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR ^L858R, EGFR ^L858R/T790M, and EGFR ^{L858R/T790M/C797S}, respectively.

EGFR-IN-5	EGFR	Cancer
EGFR-IN-5 is a *EGFR* inhibitor with IC₅₀s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR ^L858R, EGFR ^L858R/T790M, and EGFR ^{L858R/T790M/C797S}, respectively.

HY-163094

EGFR-IN-95	EGFR	Cancer
EGFR-IN-95 (compound 5j) is an 2,4-diaminonicotinamide derivative. EGFR-IN-95 has potent inhibitory activity against *EGFR* del19/T790M/C797S and L858R/T790M/C797S .

HY-161126

EGFR-IN-98	EGFR	Cancer
EGFR-IN-98 (Compound 4c) is a *EGFR* inhibitor. The IC₅₀ values of L858R/T790M/C797S and Del19/T790M/C797S are 0.277 μM and 0.089 μM, respectively. EGFR-IN 98 can be used in the study of tumors .

HY-150905

EGFR ligand-2	EGFR	Cancer
EGFR ligand-2 (compound C4), a covalent *EGFR* ligand, is a EGFR mutant inhibitor with IC₅₀s of 21 nM and 48 nM for EGFR ^L858R and EGFR ^L858R/T790M, respectively. EGFR ligand-2 can be used to synthesize PROTAC .

HY-161269

EGFR-IN-101	EGFR	Cancer
EGFR-IN-101 (I-10) is a 2-phenylamino pyrimidine derivative. EGFR-IN-101 is a *EGFR* inhibitor. The IC₅₀ values for EGFR ^{L858R/T790M/C797S} and Ba/F3-EGFR ^{L858R/T790M/C797S} are 33.26 and 106.4 nM, respectively. EGFR-IN-101 can be used IN the study of non-small cell lung cancer (NSCLC) .

HY-138072

EMI1	EGFR	Cancer
EMI1 is an **EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S** inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .

HY-146782

EGFR-IN-49	EGFR	Cancer
EGFR-IN-49 is a potent and selective *EGFR* inhibitor with IC₅₀s of 65.0 nM and 13.6 nM for EGFR ^T790M and EGFR ^T790M/L858R, respectively. EGFR-IN-49 induces late apoptosis in a dose-dependent manner .

HY-150610

EGFR-IN-69	EGFR	Cancer
EGFR-IN-69 (compound 17g) is a potent *EGFR* inhibitor, with IC₅₀ values of 4.3, 6.6 and 25.6 nM against EGFR ^{L858R/T790M/C797S}, EGFR ^L858R/T790M, and EGFR ^{19del/T790M/C797S}, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .

HY-155227

*ALK/EGFR-IN-1*	Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
ALK/EGFR-IN-1 (Compound 8l) is an *ALK/EGFR* dual inhibitor that blocks the phosphorylation of EGFR and ALK. ALK/EGFR-IN-1 inhibits ALK/EGFR mutants respectively, with IC₅₀ of 4.3 nM for EGFR L858R T790M in H1975 cells and EML4-ALK in BaF3 cells, respectively. and 3.6 nM. ALK/EGFR-IN-1 may be used in NSCLC research .

HY-130608

*Mutated EGFR-IN-3*	EGFR	Cancer
Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the *EGFR(L858R/T790M)* and *EGFR(L858R/T790M/C797S)* mutants with IC₅₀ values of 12 nM and 13 nM, respectively .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation *EGFR*-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-128860

*Mutated EGFR-IN-2*	EGFR	Cancer
Mutated EGFR-IN-2 (compound 91) is a mutant-selective *EGFR* inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC₅₀=＜1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity .

HY-12972

Mavelertinib PF-06747775	EGFR	Cancer
Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC₅₀s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .

HY-157166

EGFR kinase inhibitor 2	EGFR	Cancer
EGFR kinase inhibitor 2 (compound A-7) is a potent *EGFR* inhibitor targeting EGFR ^{L858R/T790M/C797S} and EGFR ^{Del19/T790M/C797S} mutants. EGFR kinase inhibitor 2 has the potential to address acquired resistance in the treatment of non-small cell lung cancer .

HY-19617A

EGFR-IN-1 hydrochloride	EGFR	Cancer
EGFR-IN-1 hydrochloride is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .

HY-146136

EGFR-IN-56	EGFR Apoptosis	Cancer
EGFR-IN-56 (Compound 13a) is a potent *EGFR* inhibitor with IC₅₀ values of 541.7 nM and 132.1 nM against EGFR ^T790M and EGFR ^T790M/L858R, respectively. EGFR-IN-56 blocks cancer cells in G2/M phase and induce into late apoptosis .

HY-19617

EGFR-IN-1
EGFR-IN-1 (compound 24) is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .

HY-19617B

EGFR-IN-1 TFA	EGFR	Cancer
EGFR-IN-1 TFA is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 TFA displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity .

HY-13984

*Mutant EGFR* inhibitor**	EGFR	Cancer
Mutant EGFR inhibitor is a potent and selective mutant *EGFR* inhibitor extracted from patent WO 2013014448 A1; inhibits EGFR ^L858R, EGFR ^{Exon 19 deletion} and EGFR ^T790M.

HY-157432

EGFR-IN-97	EGFR Apoptosis	Cancer
EGFR-IN-97 (compound 6q) is a *EGFR* inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR ^{L858R/T790M/C797S} and Ba/F3-EGFR ^{Del19/T790M/C797S} cells, with IC₅₀ values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR ^{L858R/T790M/C797S} cells at the concentration of 0.8 μM .

HY-15772S1

Osimertinib-13C,d3 AZD-9291-<sup>13sup>C,d₃; Mereletinib-<sup>13sup>C,d₃	EGFR	Cancer
Osimertinib- ¹³C,d₃ is the deuterium and ¹³C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.

HY-144044

EGFR-IN-30	EGFR	Cancer
EGFR-IN-30 is a potent *EGFR* inhibitor with IC₅₀s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research .

HY-12026

WZ4002 5+ Cited Publications	EGFR	Cancer
WZ4002 is a mutant selective *EGFR* inhibitor with IC₅₀s of 2, 8, 3 and 2 nM for EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^E746_A750 and EGFR ^{E746_A750/T790M}, respectively.

HY-78869

*Mutated EGFR-IN-1* Osimertinib analog	EGFR	Cancer
Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated *EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790*M resistance mutant.

HY-139920

Oritinib SH-1028	EGFR	Cancer
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFR ^WT, EGFR ^L858R, EGFR ^L861Q, EGFR ^L858R/T790M, EGFR ^d746-750 and EGFR ^{d746-750/T790M} kinases, with IC₅₀s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively .

HY-12001

WZ-3146	EGFR	Cancer
WZ3146 is a mutant selective *EGFR* inhibitor with IC₅₀s of 2, 2, 5, 14 and 66 nM for EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^E746_A750, EGFR ^{E746_A750/T790M} and EGFR, respectively.

HY-161319

EGFR-IN-104	EGFR	Cancer
EGFR-IN-104 (Compound A23) is an effective inhibitor of *EGFR, with IC₅₀* values of 0.33 μM and 0.133 μM against EGFR ^L858R/T790M and EGFR ^{Del19/T790M/C797S}, respectively. EGFR-IN-104 exhibits anticancer activity both in vitro and in vivo .

HY-151981

EGFR-IN-74

EGFR Cancer

EGFR-IN-74 (Compound 21) is a potent EGFR inhibitor with an IC₅₀ of 138 nM against EGFR L858R/T790M. EGFR-IN-74 induces cancer cell apoptosis .

EGFR-IN-74	EGFR	Cancer
EGFR-IN-74 (Compound 21) is a potent *EGFR* inhibitor with an IC₅₀ of 138 nM against EGFR L858R/T790M. EGFR-IN-74 induces cancer cell apoptosis .

HY-10346

AV-412 2 Publications Verification MP412	EGFR	Cancer
AV-412 (MP412) is an *EGFR* inhibitor with IC₅₀s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR ^L858R, EGFR ^T790M, EGFR ^L858R/T790M and ErbB2, respectively.

HY-155005

EGFR mutant-IN-2	EGFR	Cancer
EGFR mutant-IN-2 (Compound D51) is an *EGFR* mutant inhibitor. EGFR mutant-IN-2 inhibits the EGFR ^{L858R/T790M/C797S} mutant with an IC₅₀ value of 14 nM. EGFR mutant-IN-2 inhibits the EGFR ^{del19/T790M/C797S} mutant with an IC₅₀ value of 62 nM. EGFR mutant-IN-2 has favorable PK parameters, safety properties, in vivo stability, and antitumor activity .

HY-100213

EAI045 1 Publications Verification	EGFR	Cancer
EAI045 is an allosteric and the fourth-generation inhibitor of mutant *EGFR* with IC₅₀s of 1.9, 0.019, 0.19 and 0.002 μM for EGFR, EGFR ^L858R, EGFR ^T790M and EGFR ^L858R/T790M at 10 μM ATP, respectively.

HY-161031

EGFR-IN-93

EGFR Cancer

EGFR-IN-93 (compound 18) is an allosteric inhibitor of T790M/L858R double mutant EGFR. EGFR-IN-93 can be used for non-small lung cancer (NSCLC) research .

EGFR-IN-93	EGFR	Cancer
EGFR-IN-93 (compound 18) is an allosteric inhibitor of T790M/L858R double mutant *EGFR. EGFR*-IN-93 can be used for non-small lung cancer (NSCLC) research .

HY-10346A

AV-412 free base 2 Publications Verification MP-412 free base	EGFR	Cancer
AV-412 free base (MP-412 free base) is an *EGFR* inhibitor with IC₅₀s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFR ^L858R, EGFR ^T790M, EGFR ^L858R/T790M and ErbB2, respectively.

HY-139884

EGFR-IN-18

EGFR Cancer

EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM).

EGFR-IN-18	EGFR	Cancer
EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant *EGFR* (4.9 nM), with a significantly lower activity for wild-type *EGFR* (47 nM).

HY-112823B

Almonertinib hydrochloride 3 Publications Verification HS-10296 hydrochloride	EGFR	Cancer
Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer .

HY-112823

Almonertinib 3 Publications Verification HS-10296	EGFR	Cancer
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .

HY-15772

Osimertinib 85+ Cited Publications AZD-9291; Mereletinib	EGFR	Cancer
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-15772A

Osimertinib mesylate 85+ Cited Publications AZD-9291 mesylate; Mereletinib mesylate	EGFR	Cancer
Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective *EGFR* inhibitor with an apparent IC₅₀ of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR ^WT, EGFR ^T790M, EGFR ^L858R and JAK3 with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR ^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR ^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio .

HY-146210

EGFR-IN-50	EGFR	Cancer
EGFR-IN-50 (Compound 9h) is a potent *EGFR* inhibitor against L858R resistance mutation (TEL-EGFR-L858R-BaF3: GI₅₀=8 nM, TEL-EGFR-T790M-L858R-BaF3: GI₅₀=6.03 μM). EGFR-IN-50 shows anti-proliferative activity to cancer cells .

HY-112823A

Almonertinib mesylate 3 Publications Verification HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation *EGFR* tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1055 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1055 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L009

Kinase Inhibitor Library

3137 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3137 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L075

Anti-Lung Cancer Compound Library

1835 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L177

Antibody Inhibitor Library

21 Compounds compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 21 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

HY-L080

Targeted Therapy Drug Library

107 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 107 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L008

JAK/STAT Compound Library

423 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 423 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

HY-L073

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-D1583

Cyanine5 DBCO

1 Publications Verification

DBCO-Cy5; Cyanine5 dibenzocyclooctyne

Fluorescent Dyes/Probes

Cyanine5 DBCO (DBCO-Cy5) is a low-toxicity azide reactive probe (NIR fluorescent dye), for imaging azide-labeled biomolecules via a copper-free "click-through" reaction. Cyanine5 DBCO has no apparent cytotoxicity or animal toxicity and shows no damage to the physiological functions of cells other than the target cells (azide-labeled cells). Cyanine5 DBCO can be used to label and track cells in vitro and in vivo (Ex=635 nm, Em=650-700 nm) ^[2].

HY-D1327

Cyanine3 azide chloride

Fluorescent Dyes/Probes

Cyanine3 azide chloride, an analog of Cy3 azide, is a potent green fluorescent dye. Cyanine3 azide chloride uses click chemistry coupled with Alkyne-labeled proteins. Cyanine3 azide chloride can be detected by fluorometers, imagers, and microscopes. (λ_ex=684 nm, λ_em=710 nm) ^{[1]sup >. Cyanine3 azide (chloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.}

HY-D2208

SYTM Green	Fluorescent Dyes/Probes
SYTM Green is a permeable DNA dye that fluoresces green by binding to dsDNA. SYTM Green can also be used to stain bacteria, including Gram-positive and Gram-negative bacteria. Note: SYTM Green cannot penetrate living cells, and this product is equivalent to SYTOX Green .

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Fluorescent Dye
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active *EGFR* tyrosine kinase inhibitor .

Cat. No.	Product Name	Type

HY-157926

Nitroso-PSAP	Chelators
Nitroso-PSAP is a sensitive and specific chromogenic reagent for iron (Fe ²⁺), which is used for the colorimetric determination of iron in blood after mineralization with periodic acid. TNitroso-PSAP chelates with iron (Fe ²⁺) to produce a green complex (λmax=756 nm, Epsilon = 4.5 x 10 < sup > 4 < / sup > dm < sup > 3 < / sup > mol < sup > 1 < / sup > cm < sup > 1 < / sup >) .

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Biochemical Assay Reagents
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active *EGFR* tyrosine kinase inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P2503

EGFR Protein Tyrosine Kinase Substrate

EGFR Cancer

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.
HY-P4583

Suc-Val-Pro-Phe-SBzl

Peptides Others

Suc-Val-Pro-Phe-SBzl (succinyl-valine-proline-phenylalanine thiobenzyl ester) is an inhibitor of CatG enzymes with IC₅₀ values of 111-225 mM.

HY-P1799

*[pTyr5] EGFR* (988-993)**	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P1799A

*[pTyr5] EGFR* (988-993) (TFA)**	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-P1604

ATX-II	Sodium Channel	Inflammation/Immunology
ATX-II is a specific Na ⁺ channel Modulator toxin that can be isolated from the venom of sea anemone (Anemonia sulcata). ATX-II causes delayed inactivation of the Na ^{+sup channel in cell cultures. ATX-II sensitizes skeletal muscle to Halothane (HY-B1010), Caffeine, and Ryanodine (HY-103306). ATX-II also induces pulmonary vein arrhythmogenesis and atrial fibrillation .}

HY-P3918

EGF-R (661-681) T669 Peptide

p38 MAPK Others

EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .

HY-P1604A

ATX-II TFA	Sodium Channel	Inflammation/Immunology
ATX-II TFA is a specific Na ⁺ channel Modulator toxin that can be isolated from the venom of sea anemone (Anemonia sulcata). ATX-II TFA causes delayed inactivation of the Na ^{+sup channel in cell cultures. ATX-II TFA sensitizes skeletal muscle to Halothane (HY-B1010), Caffeine, and Ryanodine (HY-103306). ATX-II TFA also induces pulmonary vein arrhythmogenesis and atrial fibrillation .}

HY-P0265AS

β-Amyloid-15N (1-40) (TFA) Amyloid Beta-Peptide-<sup>15sup>N (1-40) (human) TFA; Amyloid β-Peptide-<sup>15sup>N (1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid- ¹⁵N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease[1].

HY-P5314

OK2	EGFR STAT	Others
OK2, a specific inhibitor of the *CCN2/EGFR* interaction, efficiently blocks *CCN2/EGFR* interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .

HY-W010452S1

3-Hydroxybutyric acid-13C4 sodium β-Hydroxybutyric acid-<sup>13sup>C₄ sodium	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid- ¹³C₄ (sodium) is the ¹³C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].

HY-P5340

Amyloid-Forming peptide GNNQQNY	Peptides	Others
Amyloid-Forming peptide GNNQQNY is a biological active peptide. (This is a heptapeptide from the N-terminal prion-determining domain of the yeast protein Sup35 that forms amyloid fibrils. The availability of its detailed atomic oligomeric structure makes it a good model for studying the early stage of aggregation. The GNNQQNY dimer forms three stable sheet structures. in-register parallel, off-register parallel, and anti-parallel. The in-register parallel dimer, which is close to the amyloid beta-sheet structure, has few interpeptide hydrogen bonds, making hydrophobic interactions more important and increasing the conformational entropy compared to the anti-parallel sheet.)

HY-P1363S

β-Amyloid-15N (1-42), human TFA Amyloid β-peptide-<sup>15sup>N (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1].

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-P10128

GE11	Peptides	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

Cat. No.	Product Name	Target	Research Area

HY-P99041A

*Panitumumab (anti-EGFR)*	EGFR	Cancer
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .

HY-P99892

Serclutamab

PR-1594407; DC-1630423
EGFR Others

Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P9968

Nimotuzumab	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting *EGFR* with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P99324

Tomuzotuximab Anti-Human EGFR Recombinant Antibody	EGFR Apoptosis	Cancer
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against *EGFR*. Tomuzotuximab has anticancer effects .

HY-P99295

Imgatuzumab RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody	EGFR	Cancer
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the *EGFR*. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human *EGFR-MET* bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-P99306

Modotuximab DS 1024; Sym 004	Inhibitory Antibodies	Cancer
Modotuximab (Anti-Human EGFR Recombinant Antibody) is an IgG1κ-type chimeric antibody targeting human *EGFR* protein. Modotuximab contains a portion of Futuximab that binds to two independent, non-overlapping epitopes on EGFR. Modotuximab promotes cross-linking of EGFR on the cell surface and promotes EGFR cellular internalization and degradation. Modotuximab has antitumor activity in vivo .

HY-P9969

Matuzumab

EMD 72000
EGFR Cancer

Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

HY-P9905

Cetuximab Maximum Cited Publications 25 Publications Verification C225	EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific *anti-EGFR/HER3* monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti *EGFR* monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-P99455

Bafisontamab

EMB-01
EGFR c-Met/HGFR Cancer

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
HY-P99628

Futuximab

EGFR Cancer

Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
HY-P99684

Laprituximab

J2898A
EGFR Cancer

Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
HY-P9964

Necitumumab

EGFR Cancer

Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
HY-P99888

Pimurutamab

EGFR Others

Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	EGFR	Cancer
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .

HY-P990049

Becotatug

JMT-101
EGFR Cancer

Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC .

HY-P99831

Coprelotamab GB-221	EGFR	Others
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .

HY-P99041

Panitumumab 1 Publications Verification ABX-EGF	EGFR	Cancer
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .

HY-P99155

Zalutumumab	EGFR	Cancer
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting *EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀*s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of *EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3872

Ethyl β-D-glucopyranoside	Scabiosa stellata L. Structural Classification Natural Products Caprifoliaceae Source classification Plants	Others
Ethyl β-D-glucopyranoside (compound 10) is a kind of phenolic compound. Ethyl β-D-glucopyranoside can be isolated from ethanolic extract of Scabiosa stellata LS.

HY-N11122

7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol	Structural Classification Natural Products Rhodiola rosea Linn. Source classification Crassulaceae Plants	Others
7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol is a cuminol glycoside. 7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol can be isolated from Rhodiola rosea sup>[1].

HY-N8824

Maackiaflavanone	Structural Classification Flavonoids Leguminosae Flavonones Source classification Maackia amurensis Rupr. et Maxim. Plants	Others
Maackiaflavanone (compound 4) is a kind of prenylated flavanone. Maackia can be isolated from M. amurensi.

HY-N8859

Isoiridogermanal 16-Hydroxyiridal	Structural Classification Natural Products Source classification Lridaceae Plants	Others
Isoiridogermanal can be isolated from the extract of rhizomes of Iris tectorum Maxim. Isoiridogermanal is cytotoxic with IC50 values of 11 μM and 23 μM against MCF-7 and C32 cell lines.

HY-N8930

Eupatorin-5-methyl ether	Structural Classification Galinsoga parviflora Cav. Flavonoids Flavones Labiatae Source classification Plants	Others
Eupatorin-5-methyl ether (TMF) can be isolated from Orthosiphon stamineus. Eupatorin-5-methyl ether is a kind of flavonoid compound. Eupatorin-5-methyl ether inhibits NO production (IC50 5.5 μM).

HY-N0211

Cyasterone	Classification of Application Fields Labiatae Source classification Amaranthaceae Plants Laggera crispata (Vahl) Hepper & J. R. I. Wood Disease Research Fields Achyranthes bidentata Steroids Cancer	EGFR Apoptosis
Cyasterone, a natural *EGFR* inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .

HY-N6577

Astragaloside VI	Triterpenes other families Leguminosae Terpenoids Source classification Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants	EGFR
Astragaloside VI could activate *EGFR/ERK* signalling pathway to improve wound healing.

HY-127067

Yuanhuadin	Structural Classification Terpenoids Thymelaeaceae Source classification Diterpenoids Plants Daphne genkwa Sieb. et Zucc.	Akt EGFR mTOR
Yuanhuadin, extracted from Genkwa Flos Daphne genkwa, has antitumor activity through inhibiting Akt/mTOR and *EGFR* pathways, induce cell-cycle arrest and abortion .

HY-13595

Chrysophanol 3 Publications Verification Chrysophanic acid	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Anthraquinones Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of *EGFR* and suppresses activation of AKT and mTOR/p70S6K.

HY-14596

Genistein Maximum Cited Publications 39 Publications Verification NPI 031L	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Sunscreen Leguminosae Glycine max (L.) merr Phenols Polyphenols Cosmetic Research Disease Research Fields Glycyrrhiza uralensis Fisch. Isoflavones Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis*, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-113599

Isoprocurcumenol	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Other Diseases Cosmetic Research Plants Disease Research Fields Zingiberaceae Curcuma comosa Roxb.	EGFR ERK Akt
Isoprocurcumenol is a guaiane type sesquiterpene, that can be isolated from Curcuma comosa. Isoprocurcumenol can activate *EGFR* signaling. Isoprocurcumenol increases the phosphorylation of ERK and AKT. Isoprocurcumenol promotes the proliferation of keratinocytes .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	Quinones Structural Classification Classification of Application Fields Rheum palmatum L. Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of *EGFR* and suppresses activation of AKT and mTOR/p70S6K.

HY-14596R

Genistein (Standard) Maximum Cited Publications 39 Publications Verification NPI 031L (Standard)	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Sunscreen Leguminosae Glycine max (L.) merr Phenols Cosmetic Research Disease Research Fields Glycyrrhiza uralensis Fisch. Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis*, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-N2450

Sulforaphene	Structural Classification Natural Products Classification of Application Fields Source classification Plants Brassicaceae Disease Research Fields Cancer Raphanus sativus Linn.	Apoptosis EGFR ERK NF-κB Microtubule/Tubulin
Sulforaphene, isolated from radish seeds, exhibits an ED₅₀ against velvetleaf seedlings approximately 2 x 10 ^-4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting *EGFR, p-ERK1/2, NF‐κB* and other signals .

HY-N2409

Delphinidin chloride	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Plants Anthocyans Flavonoids other families Microorganisms Solanum melongena L. Phenols Polyphenols Solanaceae Disease Research Fields Cancer	Apoptosis EGFR JAK STAT
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N4201

β-Hydroxyisovalerylshikonin	Quinones Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer	EGFR Src
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells .

HY-16558

Butein 3 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for *EGFR* and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N2510

Myristicin Myristicine	Structural Classification Simple Phenylpropanols Source classification Myristicaceae Phenylpropanoids Plants Myristica fragrans Houtt.	5-HT Receptor EGFR ERK Apoptosis Bacterial
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the *EGFR/ERK* signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	Infection Cardiovascular Disease Structural Classification Natural Products Microorganisms Neurological Disease Classification of Application Fields Source classification Metabolic Disease Disease Research Fields	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-108016

Peruvoside Encordin	Apocynaceae Triterpenes Structural Classification Terpenoids Source classification Thevetia peruviana (Pers.) K. Schum. Plants	Src PI3K JNK STAT EGFR Apoptosis Autophagy
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and *EGFR. Peruvoside induces apoptosis* and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

HY-N0281

Daphnetin 2 Publications Verification 7,8-Dihydroxycoumarin	Classification of Application Fields Daphne Thymelaeaceae Source classification Coumarins Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Cancer	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1ß, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-108052

Delphinidin 3-glucoside chloride Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Classification of Application Fields Hibiscus sabdariffa Linn. Source classification Plants Disease Research Fields Cancer	EGFR Apoptosis Akt
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Species:	Human (24) Rhesus Macaque (3) Mouse (3) Rat (2) Cynomolgus (3) Canine (1)
Tag:	His (29) Avi (11) Myc (1) GST (2) Fc (6)
Source:	HEK293 (28) CHO (1) Sf9 insect cells (6) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73634

	SNAP25 Protein, Human (His) Synaptosomal-associated protein 25; SNAP-25; sup; SNAP	Human	E. coli
	SNAP25 is a key t-SNARE in neurotransmitter release, regulating synaptic function and plasma membrane recycling. It cooperates with CENPF to affect vesicle docking and membrane fusion. SNAP25 Protein, Human (His) is the recombinant human-derived SNAP25 protein, expressed by E. coli , with N-His labeled tag. The total length of SNAP25 Protein, Human (His) is 206 a.a., with molecular weight of ~28 kDa.

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuEpidermal Growth Factor Receptor/EGFR vIII, His; Epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His) is 354 a.a., with molecular weight of 61-75 kDa.

HY-P700693

CLEC14A Protein, Human (HEK293, His)

Epidermal growth factor receptor 5; EGFR-5; EGFR 5; EGFR5; C14orf27; UNQ236; PRO269; CEG1
Human HEK293

HY-P72986

	EGFR Protein, Canine (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Canine	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein participate in the NF-kappa-B signaling pathway. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein, Canine (sf9, His) is the recombinant canine-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Canine (sf9, His) is 618 a.a., with molecular weight of ~87.2 kDa.

HY-P72988

	EGFR Protein, Mouse (HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Mouse (HEK293, Fc) is 623 a.a., with molecular weight of ~142.57 kDa.

HY-P72989

	EGFR Protein, Mouse (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, His) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Mouse (HEK293, His) is 647 a.a., with molecular weight of ~100 kDa.

HY-P72990

	EGFR Protein, Rat (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rat	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Rat (HEK293, His) is the recombinant rat-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Rat (HEK293, His) is 622 a.a., with molecular weight of 93-110 kDa.

HY-P75259

	EGFR Protein, Cynomolgus (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (sf9, His) is 621 a.a., with molecular weight of ~70.1 kDa.

HY-P75260

	EGFR Protein, Cynomolgus (HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (HEK293, His) is 621 a.a., with molecular weight of ~93.8 kDa.

HY-P702751

EGFR Protein, Human (sf9, GST)

Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1
Human Sf9 insect cells

HY-P72987

	EGFR Protein, Human (sf9, His-GST) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, His-GST) is the recombinant human-derived EGFR protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of EGFR Protein, Human (sf9, His-GST) is 543 a.a., with molecular weight of ~89.1 kDa.

HY-P75256

	EGFR Protein, Rhesus Macaque (sf9, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Rhesus Macaque (sf9, His) is 645 a.a., with molecular weight of ~70.1 kDa.

HY-P75258

	EGFR Protein, Rhesus Macaque (HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Rhesus Macaque (HEK293, Fc) is 645 a.a., with molecular weight of ~95.4 kDa.

HY-P701267

	*FITC-labeled EGFR* Protein, Human (HEK293, Fc)** EGFR; ERBB; ERBB1; HER1; PIG61; mENA	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. FITC-labeled EGFR Protein, Human (HEK293, Fc) is the recombinant human-derived FITC-labeled EGFR protein, expressed by HEK293 , with Fc labeled tag. The total length of FITC-labeled EGFR Protein, Human (HEK293, Fc) is 621 a.a., with molecular weight of 130-150 kDa.

HY-P74177

	EGFR Protein, Human (621a.a, HEK293, Fc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (621a.a, HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-hFc labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, Fc) is 621 a.a., with molecular weight of 110-160 kDa.

HY-P73517

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is 621 a.a., with molecular weight of ~99.5 kDa.

HY-P75257

	EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag. The total length of EGFR Protein, Rhesus Macaque (645a.a, HEK293, His) is 621 a.a., with molecular weight of ~93.85 kDa.

HY-P700409

	EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) Epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Myc, N-10*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is 621 a.a., with molecular weight of 73.6 kDa.

HY-P70608

	EGFR Protein, Human (HEK293, Fc) Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Human (HEK293, Fc) is 354 a.a., with molecular weight of 90-120 kDa.

HY-P78435

	EGFR Protein, Human (HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (HEK293, His-Avi) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of EGFR Protein, Human (HEK293, His-Avi) is 621 a.a., with molecular weight of 85-110 kDa.

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, His) is 621 a.a., with molecular weight of 90-120 kDa.

HY-P78118

	EGFR Protein, Human (Biotinylated, HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of EGFR Protein, Human (Biotinylated, HEK293, His-Avi) is 621 a.a., with molecular weight of 80-110 kDa.

HY-P78432

	EGFR vIII Protein, Human (HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR vIII Protein, Human (HEK293, His-Avi) is the recombinant human-derived EGFR vIII protein, expressed by HEK293, with N-Avi, N-His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His-Avi) is 621 a.a., with molecular weight of 68-80 kDa.

HY-P78436

	EGFR Protein, Human (FITC, HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR Protein, Human (FITC, HEK293, His-Avi) is the recombinant human-derived EGFR protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of EGFR Protein, Human (FITC, HEK293, His-Avi) is 621 a.a., with molecular weight of 90-115 kDa.

HY-P78117

	EGFR vIII Protein, Human (Biotinylated, HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of EGFR vIII Protein, Human (Biotinylated, HEK293, His-Avi) is 354 a.a., with molecular weight of 65-80 kDa.

HY-P78433

	EGFR vIII Protein, Human (FITC, HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	EGFR Protein, a receptor tyrosine kinase, binds various ligands like EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, initiating signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs. EGFR can also trigger NF-kappa-B signaling, phosphorylate proteins like RGS16, and interact with MUC1, influencing G protein-coupled receptor signaling. Moreover, it enhances cell migration through interactions with CCDC88A, promoting EGFR signaling and triggering cell migration. Additionally, EGFR impacts learning, memory, and pain signaling. EGFR vIII Protein, Human (FITC, HEK293, His-Avi) is the recombinant human-derived EGFR vIII protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of EGFR vIII Protein, Human (FITC, HEK293, His-Avi) is 621 a.a., with molecular weight of 68-80 kDa.

HY-P78434

	EGFR vIII Protein, Human (PE-Labeled, HEK293, His-Avi) ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR vIII Protein, Human (PE-Labeled, HEK293, His-Avi) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of EGFR vIII Protein, Human (PE-Labeled, HEK293, His-Avi) is 621 a.a., with molecular weight of ~41.6 kDa.

HY-P7340

	EGFR Protein, Human (621a.a, CHO, His) rHuEGFR, His; ERBB; ERBB1; HER1	Human	CHO
	EGFR Protein, Human (CHO, His) is a transmembrane protein with His tag. EGFR Protein exerts tyrosine kinase activity upon ligand induced activation.

HY-P7316

	EGFR Protein, Human (621a.a, Sf9, His) rHuEGFR, His; ErbB1; HER1; ERBB	Human	Sf9 insect cells
	EGFR Protein, Human (Sf9, His) is a glycosylated polypeptide chain with the C-termimal 6×His Tag produced in Sf9 insect cells. EGFR, belongs to a family of tyrosine kinase receptors, plays important roles in cell growth and differentiation.

HY-P76828

CLEC14A Protein, Mouse (HEK293, His)

C-type lectin domain family 14 member A; EGFR-5; C14orf27
Mouse HEK293
HY-P76829

CLEC14A Protein, Rat (HEK293, Fc)

C-type lectin domain family 14 member A; EGFR-5; C14orf27
Rat HEK293

HY-P700887

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is 630 a.a., with molecular weight of 85-105 kDa.

HY-P78138

	HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) is 630 a.a., with molecular weight of 80-100 kDa.

HY-P78451

	HER2/CD340 Protein, Human (630a.a, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	HER2/CD340 Protein, a dynamic tyrosine kinase, is crucial in neuregulin-receptor complexes and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibiting GSK3B and facilitating APC and CLASP2 association at the cell membrane for microtubule stabilization. In the nucleus, HER2/CD340 Protein activates PTGS2/COX-2 and rRNA genes, contributing to transcriptional regulation and protein synthesis. Its multifaceted activities emphasize its central role in cellular processes, spanning receptor signaling, microtubule dynamics, and transcriptional control. HER2/CD340 Protein, Human (630a.a, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of HER2/CD340 Protein, Human (630a.a, HEK293, His-Avi) is 630 a.a., with molecular weight of 80-100 kDa.

HY-P78453

	HER2/CD340 Protein, Human (142a.a, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	HER2/CD340 Protein, a dynamic tyrosine kinase, is crucial in neuregulin-receptor complexes and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibiting GSK3B and facilitating APC and CLASP2 association at the cell membrane for microtubule stabilization. In the nucleus, HER2/CD340 Protein activates PTGS2/COX-2 and rRNA genes, contributing to transcriptional regulation and protein synthesis. Its multifaceted activities emphasize its central role in cellular processes, spanning receptor signaling, microtubule dynamics, and transcriptional control. HER2/CD340 Protein, Human (142a.a, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of HER2/CD340 Protein, Human (142a.a, HEK293, His-Avi) is 142 a.a., with molecular weight of 28-40 kDa.

HY-P700643

	HER2/CD340 Protein, Human (Biotinylated, 142a.a, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; herstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	HER2/CD340 Protein, a dynamic tyrosine kinase, is crucial in neuregulin-receptor complexes and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibiting GSK3B and facilitating APC and CLASP2 association at the cell membrane for microtubule stabilization. In the nucleus, HER2/CD340 Protein activates PTGS2/COX-2 and rRNA genes, contributing to transcriptional regulation and protein synthesis. Its multifaceted activities emphasize its central role in cellular processes, spanning receptor signaling, microtubule dynamics, and transcriptional control. HER2/CD340 Protein, Human (Biotinylated, 142a.a, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293, with C-His, C-Avi labeled tag. The total length of HER2/CD340 Protein, Human (Biotinylated, 142a.a, HEK293, His-Avi) is 142 a.a., with molecular weight of 28-40 kDa.

Cat. No.	Product Name	Chemical Structure

HY-15772S1

Osimertinib-13C,d3
Osimertinib- ¹³C,d₃ is the deuterium and ¹³C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.

HY-15772S

Osimertinib-d6
Osimertinib-d₆ is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].

HY-15164AS

Icotinib-d4

Icotinib-d₄ is the deuterium-labeled Icotinib (HY-15164A). Icotinib-d₄ (BPI-2009) is a potent and specific EGFR inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib-d₄ is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0793S1

AZ-5104-d2
AZ-5104-d₂ is the deuterium labeled AZ-5104. AZ-5104 is an EGFR inhibitor with IC50s of 1 nM, 6 nM, 1 nM, 25 nM and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively[1].

HY-10261S1

Afatinib-d4
Afatinib-d₄ is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-10261AS

Afatinib-d6 dimaleate
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1][2].

HY-15306S

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-50896S1

Erlotinib-13C6

Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-12008S1

Erlotinib-13C6 hydrochloride
Erlotinib- ¹³C₆ (hydrochloride) is the ¹³C labeled Erlotinib Hydrochloride[1]. Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM[2]. Erlotinib-13C6 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0733S2

Glucosamine-13C,15N hydrochloride
Glucosamine- ¹³C, ¹⁵N (hydrochloride) is the ¹³C and ¹⁵N labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, i

HY-N0650S6

L-Serine1-13C,15N
L-Serine1- ¹³C, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.

HY-A0061S

Trifluridine-13C,15N2
Trifluridine- ¹³C, ¹⁵N₂ is the ¹³C and ¹⁵N labeled Trifluridine[1]. Trifluridine (Trifluorothymidine;5-Trifluorothymidine;TFT) is an irreversible thymidylate synthase inhibitor, and thereby suppresses DNA synthesis. Trifluridine is an antiviral agent for herpes simplex virus (HSV) infection. Trifluorothymidine also has anti-orthopoxvirus activity[2].

HY-Y0418S

Dulcite-13C

Dulcite- ¹³C is the ¹³C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].

HY-13458S1

Droxidopa-13C2,15N hydrochloride
Droxidopa- ¹³C₂, ¹⁵N (hydrochloride) is deuterium labeled Droxidopa. Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a proagent to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood–brain barrier[1][2].

HY-66005S4

Acetaminophen-13C2,15N
Acetaminophen- ¹³C₂, ¹⁵N is the ¹³C and ¹⁵N labeled Acetaminophen[1]. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM;is a widely used antipyretic and analgesic agent[2][3][4]. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor[5].

HY-B0389S10

D-Glucose-13C
D-Glucose- ¹³C is the ¹³C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].

HY-B0389S29

D-Glucose-18O
D-Glucose- ¹⁸O is the ¹⁸O labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules

HY-Y1250S6

Fmoc-Gly-OH-13C2,15N
Fmoc-Gly-OH- ¹³C₂, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled Crystal Violet. Crystal violet (Basic Violet 3) is a triarylmethane dye. Crystal Violet (Gentian Violet) has antiviral effects against H1N1 and also has prominent bactericidal activities.

HY-N1480S

(-)-Fucose-13C
(-)-Fucose- ¹³C is the ¹³C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[1]

HY-125818S2

Cytidine-5'-triphosphate-13C,d1 dilithium

Cytidine-5'-triphosphate- ¹³C,d₁ (Cytidine triphosphate- ¹³C,d₁ dilithium; 5'-CTP- ¹³C,d₁) dilithium is deuterium and ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

HY-W067028S

Semicarbazide-13C,15N2 hydrochloride

Semicarbazide- ¹³C, ¹⁵N₂ hydrochloride is ¹⁵N and ¹³C labeled Semicarbazide.
HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-A0070AS1

Liothyronine-13C9,15N
Liothyronine- ¹³C₉, ¹⁵N is the ¹³C and ¹⁵N labeled Liothyronine[1]. Liothyronine is an active form of thyroid hormone. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[2][3][4].

HY-B0215S1

Acetylcysteine-15N

Acetylcysteine- ¹⁵N (N-Acetylcysteine- ¹⁵N) is the ¹⁵N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor[1]. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases[5]. Acetylcysteine induces cell apoptosis[2][3]. Acetylcysteine also has anti-influenza virus activities[7].

HY-Y0504S2

Trimethylammonium chloride-15N

Trimethylammonium chloride- ¹⁵N is the ¹⁵N labeled Trimethylammonium chloride[1]. Trimethylammonium chloride is an endogenous metabolite.

HY-B0150S1

Nicotinamide-15N,13C3
Nicotinamide- ¹⁵N, ¹³C₃ is the ¹³C-labeled and ¹⁵N-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.

HY-N0733S5

Glucosamine-13C6,15N hydrochloride
Glucosamine- ¹³C₆, ¹⁵N (hydrochloride) is the ¹³C and ¹⁵N labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids,

HY-13417S

AICAR-13C2,15N
AICAR- ¹³C₂, ¹⁵N (Acadesine- ¹³C₂, ¹⁵N; AICA Riboside- ¹³C₂, ¹⁵N)is the ¹³C and ¹⁵N labeledAICAR(HY-13417) . AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor .

HY-B0178AS

Guanidine-13C,15N3 hydrochloride
Guanidine- ¹³C, ¹⁵N₃ (hydrochloride)is the ¹³C-labeled and ¹⁵N-labeled Guanidine hydrochloride. Guanidine hydrochloride (Guanidinium chloride) a strong chaotrope, is also a strong denaturant of proteins[1][2].

HY-N0650S5

L-Serine-13C3,15N
L-Serine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.

HY-13677S1

6-Mercaptopurine-13C2,15N
6-Mercaptopurine- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.

HY-N0091S1

Hypoxanthine-13C,15N2
Hypoxanthine- ¹³C, ¹⁵N₂ is a ¹⁵N-labeled and ¹³C-labled Furaltadone. Furaltadone, a nitrofuran agent, has the potential for the study in infections of chickens with salmonella enteritidis. Furaltadone is inhibitory and bactericidal in vitro for staphylococci

HY-N0091S3

Hypoxanthine-13C2,15N

Hypoxanthine- ¹³C₂, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled DL-Cystine[1].

HY-13623S1

Entecavir-13C2,15N
Entecavir- ¹³C₂, ¹⁵N (BMS200475- ¹³C₂, ¹⁵N; SQ34676- ¹³C₂, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC₅₀ of 3.75 nM in HepG2 cell.

HY-N0667S4

L-Asparagine-4-13C monohydrate
L-Asparagine-4- ¹³C (monohydrate) is the ¹³C-labeled L-Asparagine. L-Asparagine ((-)-Asparagine) is a non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue.

HY-Y0418S1

Dulcite-13C-1

Dulcite- ¹³C-1 is the ¹³C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
HY-Y0418S2

Dulcite-13C-2

Dulcite- ¹³C-2 is the ¹³C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
HY-Y0418S3

Dulcite-13C-3

Dulcite- ¹³C-3 is the ¹³C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].

HY-B0617S1

S-Adenosyl-L-methionine-13C

S-Adenosyl-L-methionine- ¹³C is the ¹³C labeled S-Adenosyl-L-methionine[1]. S-Adenosyl-L-methionine (S-Adenosyl methionine) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects, and has the potential for liver disease and osteoarthritis research[2][3][4].

HY-Y0842S

Formamide-13C

Formamide- ¹³C is the ¹³C-labeled Formamide. Formamide is an amide derived from formic acid and has been used as solvent for many ionic compounds.

HY-101037S

Sarcosine-15N
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-N0623S1

L-Tryptophan-13C

L-Tryptophan- ¹³C is the ¹³C-labeled L-Tryptophan. L-Tryptophan (Tryptophan) is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3[1].
HY-N0623S7

L-Tryptophan-15N

L-Tryptophan- ¹⁵N is the ¹⁵N-labeled L-Tryptophan. L-Tryptophan (Tryptophan) is an essential amino acid that is the precursor of serotonin, melatonin, and vitamin B3[1].
HY-N0378S1

D-Mannitol-13C

D-Mannitol- ¹³C is the ¹³C labeled D-Mannitol[1][2][3][4].

HY-N0733S

Glucosamine-13C hydrochloride
Glucosamine- ¹³C (hydrochloride) is the ¹³C labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a

HY-N1150S2

Thymidine-13C
Thymidine- ¹³C is the ¹³C labeled Thymidine. Thymidine, a specific precursor of deoxyribonucleic acid, is used as a cell synchronizing agent. Thymidine is a DNA synthesis inhibitor that can arrest cell at G1/S boundary, prior to DNA replication[1]

HY-N0733S4

Glucosamine-15N hydrochloride
Glucosamine- ¹⁵N (hydrochloride) is the ¹⁵N labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a

HY-N0545S

Taurocholic acid-13C2,15N sodium

Taurocholic acid- ¹³C₂, ¹⁵N (sodium) is the ¹³C- and ¹⁵N- labeled Taurocholic acid (sodium).

HY-14291S2

Vildagliptin-13C5,15N
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-B0389S11

D-Glucose-13C-1
D-Glucose- ¹³C-1 is the ¹³C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80116

EGFR Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
EGFR Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to EGFR. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80458

*Phospho-EGFR* (Y1068) Antibody (YA204)**	WB, ICC/IF, IP, FC	Human
Phospho-EGFR Antibody (YA204) is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR(Y1068). It can be used for WB,ICC/IF,IP,FC assays with tag free, in the background of Human.

HY-P81667

SNAP25 Antibody (YA1412)

Synaptosomal-associated protein 25; SNAP-25; super protein; sup; Synaptosomal-associated 25 kDa protein; SNAP25; SNAP
WB, ICC/IF, IP Human, Mouse, Rat

HY-P80648

EGFR Antibody (YA775) EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, ICC/IF, IP	Human, Monkey
EGFR Antibody (YA775) is a non-conjugated and Mouse origined monoclonal antibody about 134 kDa, targeting to EGFR (6H11). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Monkey.

HY-P80808

*Phospho-EGFR* (Tyr1068) Antibody** EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF	Human
Phospho-EGFR (Tyr1068) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1068). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P80809

*Phospho-EGFR* (Tyr1092) Antibody** EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-P	Human, Mouse, Rat
Phospho-EGFR (Tyr1092) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1092). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80810

*Phospho-EGFR* (Tyr1173) Antibody** EGFR; ERBB; ERBB1; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF, IP	Human
Phospho-EGFR (Tyr1173) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1173). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

Cat. No.	Product Name		Classification

HY-15164

Icotinib Hydrochloride 5+ Cited Publications BPI-2009H		Alkynes
Icotinib Hydrochloride (BPI-2009) is a potent and specific *EGFR* inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15164A

Icotinib 5+ Cited Publications BPI-2009		Alkynes
Icotinib (BPI-2009) is a potent and specific *EGFR* inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066

Theliatinib Xiliertinib; HMPL-309		Alkynes
Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective *EGFR* inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for *EGFR* than other kinases . Theliatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147858

*PROTAC EGFR* degrader 7**		Alkynes
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066A

Theliatinib tartrate Xiliertinib tartrate; HMPL-309 tartrate		Alkynes
Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective *EGFR* inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for *EGFR* than other kinases . Theliatinib (tartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S1

Erlotinib-13C6 CP-358774-<sup>13sup>C₆; NSC 718781-<sup>13sup>C₆; OSI-774-<sup>13sup>C₆		Alkynes
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-156497

Biotin-PEG8-Me-Tet

Labeling and Fluorescence Imaging Tetrazine

Biotin-PEG8-Me-Tet is a biotin labeling.

HY-12008S1

Erlotinib-13C6 hydrochloride CP-358774-<sup>13sup>C₆ hydrochloride; NSC 718781-<sup>13sup>C₆ hydrochloride; OSI-774-<sup>13sup>C₆ hydrochloride		Alkynes
Erlotinib- ¹³C₆ (hydrochloride) is the ¹³C labeled Erlotinib Hydrochloride[1]. Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM[2]. Erlotinib-13C6 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-D1327

Cyanine3 azide chloride		Azide Labeling and Fluorescence Imaging
Cyanine3 azide chloride, an analog of Cy3 azide, is a potent green fluorescent dye. Cyanine3 azide chloride uses click chemistry coupled with Alkyne-labeled proteins. Cyanine3 azide chloride can be detected by fluorometers, imagers, and microscopes. (λ_ex=684 nm, λ_em=710 nm) ^{[1]sup >. Cyanine3 azide (chloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.}

HY-150781

EGFR-IN-71		Alkynes
EGFR-IN-71 is a potent narrow spectrum *epidermal growth factor receptor (EGFR)* inhibitor with IC₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-17413S1

Zidovudine-13C,d3 Azidothymidine-<sup>13sup>C,d₃; AZT-<sup>13sup>C,d₃; ZDV-<sup>13sup>C,d₃		Azide
Zidovudine- ¹³C,d₃ is the ¹³C- and deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency. Zidovudine-13C,d3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-B0216S2

Ethynyl Estradiol-13C2 17α-Ethynylestradiol-<sup>13sup>C₂; Ethynylestradiol-<sup>13sup>C₂		Alkynes
Ethynyl Estradiol- ¹³C₂ is the ¹³C-labeled Ethynyl Estradiol. Ethynyl Estradiol-13C2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605BS

Rasagiline-13C3 mesylate racemic AGN1135-<sup>13sup>C₃; TVP1012-<sup>13sup>C₃ racemic		Alkynes
Rasagiline- ¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S

Erlotinib-d6 CP-358774-d₆; NSC 718781-d₆; OSI-774-d₆		Alkynes
Erlotinib-d₆ (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR[1]. Erlotinib-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896

Erlotinib Maximum Cited Publications 74 Publications Verification CP-358774; NSC 718781; OSI-774		Alkynes
Erlotinib (CP-358774) is a directly acting *EGFR* tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12008

Erlotinib Hydrochloride Maximum Cited Publications 74 Publications Verification CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride		Alkynes
Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified *EGFR* kinase with an IC₅₀ of 2 nM. Erlotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12008A

Erlotinib mesylate CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate		Alkynes
Erlotinib mesylate (CP-358774 mesylate) inhibits purified *EGFR* kinase with an IC₅₀ of 2 nM. Erlotinib (mesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19909

NRC-2694		Alkynes
NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13256

Desmethyl Erlotinib hydrochloride 3 Publications Verification OSI-420; CP-373420 hydrochloride		Alkynes
Desmethyl Erlotinib hydrochloride (OSI-420) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor . Desmethyl Erlotinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13256A

Desmethyl Erlotinib 3 Publications Verification OSI-420 free base; CP-373420		Alkynes
Desmethyl Erlotinib (OSI-420 free base) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor . Desmethyl Erlotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of HDAC, *EGFR, and HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139300

Epitinib HMPL-813		Alkynes
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer . Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139300A

Epitinib succinate HMPL-813 succinate		Alkynes
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer . Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13256AS

Desmethyl Erlotinib-d4		Alkynes
Desmethyl Erlotinib-d₄ is the deuterium labeled Desmethyl Erlotinib. Desmethyl Erlotinib (OSI-420 free base) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor[1][2]. Desmethyl Erlotinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150782

UNC-CA359		Alkynes
UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC₅₀ value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-135699

TD52 1 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 1 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry